Core Points - Veeva Systems will announce its financial results for the third quarter ending October 31, 2025, after market close on November 20, 2025 [1] - A conference call and webcast will be held on the same day at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results [1][3] - Prepared remarks will be posted on Veeva's investor relations website at approximately 1:05 p.m. PT (4:05 p.m. ET) [2] Company Overview - Veeva Systems provides industry cloud solutions for life sciences, including software, data, and business consulting [3] - The company serves over 1,500 customers, ranging from large pharmaceutical companies to emerging biotechs [3] - As a Public Benefit Corporation, Veeva is dedicated to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves [3]

Company Overview - Veeva Systems (NYSE: VEEV) is recognized for its excellent financial performance and high growth rates, with the added advantage of having no debt [1] Financial Performance - The company demonstrates strong financial metrics, which are appealing to conservative investors [1] Investment Perspective - The business model of Veeva Systems is viewed positively, indicating potential for continued growth and stability in the market [1]

Core Insights - The stock market is showing signs of complacency regarding a potential weakening macroeconomy and an intensifying trade war as 2025 approaches [1] Group 1: Market Conditions - Investors need to be cautious in deploying smart strategies amid the backdrop of a potentially weakening macroeconomy and trade tensions [1] Group 2: Analyst Background - Gary Alexander has extensive experience covering technology companies on Wall Street and working in Silicon Valley, contributing to insights on industry themes [1] - He has been a contributor on Seeking Alpha since 2017 and has been quoted in various web publications, with his articles syndicated to popular trading apps like Robinhood [1]

Group 1 - The event is the 2025 Investor Day hosted by Veeva, featuring a series of presentations and a customer comment [1] - The presentations will last approximately 60 minutes, followed by a Q&A session [1] - Technical questions can be submitted through the Q&A widget or via email to the investor relations team [1] Group 2 - Forward-looking statements will be made during the presentations, covering trends, strategies, market size, opportunities, and anticipated business performance [2] - These statements are based on the management's current expectations and assessments [2]

Group 1 - The article does not provide any specific content or key points related to a company or industry [1]

Summary of Veeva's 2025 Investor Day Company Overview - **Company**: Veeva Systems - **Industry**: Life Sciences - **Market Size**: Life sciences is a $2 trillion industry with a total addressable market (TAM) of $20 billion for Veeva's specific software and data solutions [5][26] Core Points and Arguments 1. **Vision and Values**: Veeva aims to build the industry cloud for life sciences, focusing on cloud software, data, and consulting to enhance efficiency and effectiveness in the industry [4][5] 2. **Revenue Goals**: Veeva is on track to achieve a revenue run rate of $6 billion by 2030, implying an annual growth rate of approximately 13% [5][25] 3. **Market Penetration**: Currently, Veeva has a 16% penetration in its TAM, indicating significant growth potential ahead [6][27] 4. **Product Strategy**: Veeva's product offerings include Development Cloud, Quality Cloud, Commercial Cloud, and Data Cloud, all aimed at supporting digital transformation in life sciences [8][9] 5. **AI Integration**: Veeva AI is a major initiative expected to enhance productivity across the life sciences sector, with the first release scheduled for December 2025 [19][20] 6. **Customer Success**: The company emphasizes customer success and product excellence as key drivers for long-term market leadership [10][11] Financial Performance 1. **Revenue Composition**: 92% of Veeva's revenue comes from biopharma, with the top 20 customers accounting for about half of the revenue [24][25] 2. **Operating Margins**: Non-GAAP operating margins were reported at 45% in Q2, with a target of maintaining a floor of 35% by 2030 [26] 3. **Growth Areas**: Each product area is expected to contribute to growth, with clinical operations and data management being key focus areas [27][30] Emerging Market Insights 1. **New Markets Initiative**: Veeva is exploring horizontal enterprise applications as a new market opportunity, focusing on product excellence and innovation [20][21] 2. **Customer Perspective**: Dr. Evan Bailey from Applied Therapeutics highlighted the need for efficiency in drug development and the benefits of integrated systems like Veeva for reducing costs and improving timelines [42][45] Additional Important Insights 1. **Technology as an Enabler**: The integration of technology is seen as crucial for improving efficiency in drug development processes, with a focus on having a single source of truth [46][48] 2. **Cost Savings**: Applied Therapeutics reported significant cost savings by using Veeva's integrated systems, eliminating the need for multiple CROs and reducing database maintenance fees [59][60] 3. **Future Readiness**: Veeva's systems are designed to support future commercial activities, ensuring that all functions are interconnected and ready for market launch [57][58] This summary encapsulates the key points discussed during Veeva's 2025 Investor Day, highlighting the company's strategic direction, financial performance, and insights from industry experts.

Vision and Strategy - Veeva is aiming for \$6 billion in revenue by 2030[8, 13], and is on track to achieve this goal[8, 13, 54, 66, 87] - The company estimates a \$20 billion+ total addressable market (TAM) in Life Sciences[10, 70], with approximately 16% penetrated as of FY26E[10, 70] - Veeva AI is expected to be a significant growth driver[8, 30, 53] Financial Performance and Guidance - Q3'26 total revenue guidance is \$790-\$793 million, with subscription revenue of approximately \$671 million[62] - Q3'26 non-GAAP operating income is projected at \$348-\$350 million, and non-GAAP fully diluted net income per share at \$1.94-\$1.95[62] - The company's revenue run rate today is \$3.2 billion, with a goal of \$6 billion by 2030[67] Market Segmentation and Growth - Biopharma accounts for 92% of Veeva's revenue, MedTech for 5%, and other industries for 3%[65] - The subscription revenue mix is currently 84%, with a target of approximately 87% by 2030[67] - Veeva is experiencing continued adoption in R&D, with an increasing number of customers using multiple products[94, 95]

Core Insights - Veeva Systems and OpenEvidence have formed a long-term partnership to create and market Open Vista, which aims to enhance patient access to clinical trials and improve drug discovery through AI [1][2][7] - Open Vista will focus on connecting physicians and patients to relevant clinical trials and therapies, particularly for patients with serious illnesses who have limited treatment options [2] - The first product offerings from Open Vista are expected to be released in 2026 [2] Company Overview - Veeva Systems provides cloud-based software, data, and consulting services for the life sciences industry, serving over 1,500 customers, including major biopharmaceutical companies and emerging biotech firms [3] - OpenEvidence is recognized as the fastest-growing clinical decision support platform in the U.S., with over 40% of U.S. physicians actively using its services [4] - OpenEvidence is utilized by more than 10,000 hospitals and medical centers, emphasizing its role in aiding high-stakes clinical decisions based on peer-reviewed medical literature [4]

Core Insights - Veeva Systems holds a strong market position with recurring revenue from subscription services and is well-positioned to benefit from the AI trend in healthcare [1][2] Industry Overview - The pharmaceutical industry is increasingly interested in applying AI to enhance the drug discovery process, although AI cannot predict human responses to drugs [4] - AI can improve the efficiency of the initial drug candidate selection process, which typically involves screening thousands of molecules [5] Company Analysis - Veeva Systems has been developing an industry cloud for life sciences that integrates regulatory, clinical, and commercial data, enhancing the efficiency of drug discovery [7][8] - The company offers a suite of software services tailored for the biopharmaceutical sector, including a customer relationship management service that is gaining traction [7] - With extensive data on drug sales and development, Veeva's AI services could further increase the stickiness of its software subscriptions [7]

Core Insights - Veeva Systems Inc. (VEEV) is positioned for growth due to its strong product portfolio and solid second-quarter fiscal 2026 performance, despite concerns over rising operational costs [1][8]. Financial Performance - Veeva Systems reported a revenue increase of 16.7% year over year, reaching $789 million in Q2, surpassing its guidance [5][8]. - The company has a market capitalization of $46.89 billion and anticipates a 23.5% growth over the next five years, with a trailing four-quarter average earnings surprise of 9.7% [3][5]. Growth Drivers - The robust product portfolio includes continued subscription momentum in Vault CRM, which is now adopted by nine of the top 20 pharmaceutical firms [5][10]. - The Development Cloud has shown steady expansion, with subscriptions growing at the fastest pace in two years, particularly in clinical, regulatory, and quality solutions [6][10]. - Crossix and Data Cloud offerings are key growth drivers, enhancing Veeva's integrated ecosystem in the life sciences industry [7][9]. Strategic Initiatives - Recent strategic deals with Gilead and IQVIA have strengthened Veeva's position in the life sciences sector, facilitating seamless integration of data within its Commercial and Development Clouds [9][10]. - The rollout of Veeva AI is part of the company's strategy to enhance its offerings, with initial releases planned for December and broader expansion through 2027 [12]. Cost Considerations - Operating expenses increased by 17.3% year over year, with general and administrative expenses rising by 56.1% in Q2 fiscal 2026 [13][14]. - Management anticipates further increases in sales and marketing expenses due to workforce expansion to support growth initiatives [13][14]. Estimate Trends - The Zacks Consensus Estimate for fiscal 2026 earnings per share has increased by 15 cents to $7.68, with Q3 fiscal 2026 revenue estimates at $791.9 million, reflecting a 13.3% year-over-year improvement [15].